TTM
$16.75B
YoY change
-16.7%
5Y CAGR
+2.8%
Peak year (2022)
$41.03B
Cumulative EBITDA
$514.48B
EBITDA history chart for Pfizer (PFE) from 1985 to 2025
Latest: $15.10B
EBITDA growth chart for Pfizer (PFE) from 1985 to 2025
Latest: -16.7%
EBITDA history table for Pfizer (PFE) from 1985 to 2025
| 2025 | $15.10B | -16.7% | −$3.03B | ||
| 2024 | $18.13B | +89.7% | +$8.57B | ||
| 2023 | $9.56B | -76.7% | −$31.47B | ||
| 2022 | $41.03B | +33.2% | +$10.24B | ||
| 2021 | $30.79B | +133.8% | +$17.63B | ||
| 2020 | $13.17B | -30.2% | −$5.68B | ||
| 2019 | $18.85B | -3.7% | −$732.00M | ||
| 2018 | $19.59B | -1.3% | −$259.00M | ||
| 2017 | $19.84B | +29.8% | +$4.55B | ||
| 2016 | $15.29B | -0.2% | −$27.00M | ||
| 2015 | $15.32B | -19.9% | −$3.82B | ||
| 2014 | $19.14B | -18.7% | −$4.40B | ||
| 2013 | $23.54B | +15.3% | +$3.12B | ||
| 2012 | $20.42B | -8.0% | −$1.77B | ||
| 2011 | $22.19B | +13.4% | +$2.62B | ||
| 2010 | $19.57B | +16.3% | +$2.75B | ||
| 2009 | $16.82B | +9.9% | +$1.52B | ||
| 2008 | $15.30B | +2.9% | +$425.00M | ||
| 2007 | $14.88B | -20.9% | −$3.93B | ||
| 2006 | $18.81B | +11.6% | +$1.96B | ||
| 2005 | $16.85B | -13.4% | −$2.60B | ||
| 2004 | $19.45B | +35.1% | +$5.06B | ||
| 2003 | $14.39B | +8.5% | +$1.13B | ||
| 2002 | $13.26B | +14.4% | +$1.67B | ||
| 2001 | $11.59B | +21.5% | +$2.05B | ||
| 2000 | $9.54B | +21.2% | +$1.67B | ||
| 1999 | $7.87B | +28.0% | +$1.72B | ||
| 1998 | $6.15B | +75.6% | +$2.65B | ||
| 1997 | $3.50B | +12.9% | +$399.00M | ||
| 1996 | $3.10B | +5.7% | +$167.80M | ||
| 1995 | $2.93B | +29.6% | +$669.70M | ||
| 1994 | $2.26B | +93.3% | +$1.09B | ||
| 1993 | $1.17B | -31.4% | −$535.80M | ||
| 1992 | $1.71B | +14.0% | +$209.70M | ||
| 1991 | $1.50B | +17.1% | +$219.00M | ||
| 1990 | $1.28B | +8.8% | +$103.30M | ||
| 1989 | $1.18B | -2.6% | −$31.10M | ||
| 1988 | $1.21B | +9.4% | +$103.60M | ||
| 1987 | $1.10B | -0.4% | −$4.00M | ||
| 1986 | $1.11B | +9.6% | +$97.30M | ||
| 1985 | $1.01B | — | — |
- 2025$15.10B-16.7%
- 2024$18.13B+89.7%
- 2023$9.56B-76.7%
- 2022$41.03B+33.2%
- 2021$30.79B+133.8%
- 2020$13.17B-30.2%
- 2019$18.85B-3.7%
- 2018$19.59B-1.3%
- 2017$19.84B+29.8%
- 2016$15.29B-0.2%
- 2015$15.32B-19.9%
- 2014$19.14B-18.7%
- 2013$23.54B+15.3%
- 2012$20.42B-8.0%
- 2011$22.19B+13.4%
- 2010$19.57B+16.3%
- 2009$16.82B+9.9%
- 2008$15.30B+2.9%
- 2007$14.88B-20.9%
- 2006$18.81B+11.6%
- 2005$16.85B-13.4%
- 2004$19.45B+35.1%
- 2003$14.39B+8.5%
- 2002$13.26B+14.4%
- 2001$11.59B+21.5%
- 2000$9.54B+21.2%
- 1999$7.87B+28.0%
- 1998$6.15B+75.6%
- 1997$3.50B+12.9%
- 1996$3.10B+5.7%
- 1995$2.93B+29.6%
- 1994$2.26B+93.3%
- 1993$1.17B-31.4%
- 1992$1.71B+14.0%
- 1991$1.50B+17.1%
- 1990$1.28B+8.8%
- 1989$1.18B-2.6%
- 1988$1.21B+9.4%
- 1987$1.10B-0.4%
- 1986$1.11B+9.6%
- 1985$1.01B—
EBITDA values are taken from Pfizer's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's current EBITDA (TTM) is $16.75B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Pfizer (PFE) EBITDA is $15.10B – declined 16.7% year-over-year.
Through 2020–2025 (5 years), Pfizer EBITDA delivered a +2.8% annualised rate; with mixed annual results across the window.
Pfizer EBITDA peaked at $41.03B in 2022; the latest annual figure is $15.10B in 2025 (63.2% below peak).
2022 marks the peak EBITDA at $41.03B, with the historical low of $1.01B recorded in 1985.
Pfizer EBITDA by Year
Pfizer EBITDA 2025: $15.10B
Pfizer posted EBITDA of $15.10B in 2025, declined 16.7% below 2024.
Pfizer EBITDA 2024: $18.13B
In 2024, Pfizer reported EBITDA of $18.13B, surged 89.7% from 2023.
Pfizer EBITDA 2023: $9.56B
Pfizer EBITDA in 2023 was $9.56B, plunged 76.7% below 2022.
Pfizer EBITDA 2022: $41.03B
2022's EBITDA for Pfizer came in at $41.03B, surged 33.2% from 2021. This figure represents the highest annual value in the available history.
Pfizer EBITDA 2021: $30.79B
Pfizer EBITDA in 2021 was $30.79B.
See more financial history for Pfizer (PFE).
Sector peers by EBITDA
Healthcare peers of Pfizer (PFE), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation